Financial Performance - The company's operating revenue for 2018 reached ¥1,022,164,265.75, representing a 73.08% increase compared to ¥590,580,085.29 in 2017[21] - The net profit attributable to shareholders of the listed company was ¥263,929,840.55, a decrease of 44.88% from ¥478,817,120.27 in the previous year[21] - The net profit after deducting non-recurring gains and losses was ¥188,115,826.31, which is an 11.05% increase from ¥169,390,681.23 in 2017[21] - The cash flow from operating activities was ¥263,108,138.33, showing a slight decrease of 2.73% compared to ¥270,486,916.37 in 2017[21] - The total assets of the company at the end of 2018 were ¥2,920,192,461.76, a 74.42% increase from ¥1,674,241,312.22 at the end of 2017[21] - The net assets attributable to shareholders of the listed company increased by 83.04% to ¥2,480,714,428.69 from ¥1,355,311,905.26 in 2017[21] - Basic and diluted earnings per share decreased by 50.38% to CNY 1.98 compared to CNY 3.99 in the previous year[22] - Net profit attributable to shareholders decreased by 44.88%, primarily due to high investment income from the previous year's transfer of equity in Guoyao Kangchen[23] - Revenue increased by 73.08% year-on-year, driven by the implementation of the "two-invoice system" and an increase in the average settlement price[22] - The weighted average return on net assets decreased by 28.18 percentage points to 14.79% from 42.97% in the previous year[22] Research and Development - The company focuses on innovative drug research and development, particularly in the fields of hematology and oncology[34] - R&D expenses for 2018 amounted to CNY 80.25 million, representing a significant increase of 149.48% from the previous year[51] - The company has established a comprehensive and internationalized R&D system, enhancing its capability to develop "global new" innovative drugs[42] - The company has four national Class I anti-tumor drugs in the research pipeline, with multiple patents applied for both domestically and internationally[43] - The company’s R&D investment accounted for 7.85% of its operating revenue in 2018, and 3.23% of its net assets[90] - The company is focusing on new drug development in oncology and hematology, with several projects in various stages of clinical trials[91] - The company has successfully launched the hemostatic drug "Sulingen," which has independent intellectual property rights[84] - The company’s R&D strategy aims to transition from domestic innovations to global innovations in drug development[83] Product and Market Performance - The company’s main product, "Sulink," is the only Class I new drug in the domestic hemostatic agent market, widely used in various clinical departments[34] - The company’s marketing model has proven effective, with "Sulink" achieving the leading position in its market segment within three years of its launch[44] - The sales revenue for the hemostatic drug "Suling" reached RMB 97,085.07 million, representing a year-on-year increase of 64.39%[95] - The gross profit margin for the hemostatic drug "Suling" is 95.08%, with a year-on-year increase of 6.22% in revenue[95] - The company aims to enhance its market share of "Suling" and solidify its leading position in the Chinese hemostatic market, with plans to increase hospital coverage and sales volume[108] Financial Management and Capital Structure - The company raised CNY 973.6 million from its initial public offering, with a net amount of CNY 891.4 million after deducting related expenses[38] - The company issued 40 million new shares at a price of 24.34 RMB per share, increasing total shares from 120 million to 160 million[198] - The total amount raised from the share issuance was 973.6 million RMB, with a net amount of approximately 891.43 million RMB after deducting issuance costs[199] - The total liabilities rose from 318.93 million RMB to 439.48 million RMB, resulting in a decrease in the asset-liability ratio from 19.05% to 15.05%[199] - The company has committed to maintaining a cash dividend priority policy to protect the rights of minority investors[121] Risk Management and Compliance - The company has detailed potential risks in the report, which are discussed in the section on operational conditions[7] - The company emphasizes that forward-looking statements do not constitute commitments to investors, highlighting the importance of investment risk awareness[6] - The company has established a comprehensive drug vigilance system, complying with national regulations to monitor adverse drug reactions[46] - The company has implemented measures to ensure compliance with environmental regulations and has achieved standard emissions for pollutants[186] Corporate Governance - Company executives, including Cheng Zhaoran, committed to not transferring or entrusting their shares within 12 months of the IPO[126] - The actual controllers, Liu Jianhua and Wang Xijuan, promised to avoid any business activities that compete with the company during their tenure[129] - The company will take measures to standardize and minimize related party transactions, ensuring they do not adversely affect the interests of the company and its shareholders[130] - Company directors and senior management are required to increase their holdings by at least 30% of their annual salary[145] Social Responsibility and Sustainability - The company actively participates in social responsibility initiatives and has received multiple awards for its contributions[183] - The company has initiated an EHS management system to improve workplace health and safety[182] - The company is committed to a "dumbbell" strategy, balancing innovative drug R&D with marketing efforts to ensure market acceptance of new products[107]

Financial Performance - Operating revenue for the first nine months reached CNY 695,939,785.51, a 78.57% increase year-on-year[6] - Net profit attributable to shareholders decreased by 62.69% to CNY 156,937,461.96 compared to the same period last year[6] - Basic earnings per share decreased by 64.02% to CNY 1.2611[7] - The company reported a net profit excluding non-recurring gains and losses of CNY 152,673,652.44, up 23.19% year-on-year[6] - The company expects net profit attributable to shareholders for 2018 to be approximately 253 million to 259 million CNY, a decline of 45.91% to 47.16% year-on-year[19] - Net profit attributable to shareholders (excluding non-recurring gains and losses) is expected to be approximately 193 million to 199 million CNY, an increase of 13.94% to 17.48% year-on-year[19] Assets and Liabilities - Total assets increased by 67.97% to CNY 2,812,208,293.05 compared to the end of the previous year[6] - Total liabilities as of September 30, 2018, were 399,597,071.79 CNY, up from 318,929,406.96 CNY at the beginning of the year[23] - Total equity attributable to shareholders increased to 2,412,611,221.26 CNY from 1,355,311,905.26 CNY year-on-year[23] - Cash and cash equivalents increased by 197.38% to ¥1,613,987,866.25 from ¥542,729,117.36, primarily due to funds raised from public offerings and operational accumulation[14] - Accounts receivable rose by 94.67% to ¥152,993,650.43 from ¥78,591,929.49, attributed to an increase in revenue from direct customers and distributors[15] Cash Flow - Cash flow from operating activities for the first nine months was CNY 186,783,324.35, a slight increase of 1.28% year-on-year[6] - Net cash flow from investment activities was -18,411,157.09 CNY, a decrease of 125.44% year-on-year due to significant recovery of bank financial products in the previous year[18] - Net cash flow from financing activities increased to 902,886,581.63 CNY, primarily due to funds raised by the company[18] - Cash inflows from operating activities amounted to CNY 748,250,070.91, a significant increase from CNY 459,387,383.23 year-on-year, representing a growth of approximately 62.8%[39] - The net cash flow from operating activities was CNY 186,783,324.35, slightly up from CNY 184,428,686.10 in the same period last year[40] Shareholder Information - The total number of shareholders reached 28,929 by the end of the reporting period[12] - The top shareholder, Liu Jianhua, holds 31.74% of the shares, totaling 50,786,760 shares[12] Expenses - The company's gross profit margin was impacted by a significant increase in sales expenses, which rose by 146.32% to ¥428,657,909.82 from ¥174,022,249.57[16] - Research and development expenses increased by 37.95% to ¥30,048,119.40 from ¥21,781,579.28, reflecting the company's commitment to innovation[16] - Sales expenses for the first nine months of 2018 amounted to ¥428.56 million, which is a 146.5% increase from ¥174.02 million in the same period of 2017[35] Comprehensive Income - The total comprehensive income decreased by 61.46% to ¥165,873,379.00 from ¥430,402,808.24, primarily due to the previous year's significant equity transfer gains[17] - The company's total comprehensive income for Q3 2018 was approximately ¥58.93 million, compared to ¥41.13 million in Q3 2017, indicating a growth of 43.3%[33]